With Friends Like VCs, Who Needs Public Equity?
Executive Summary
As NASDAQ investors continue to avoid the biotech sector, many biotechs have recently begun to respond in kind--by avoiding NASDAQ. Many of the largest recent financings by public biotechs have been completed privately.